Skip to contentP
Precision Biosciences Inc
P
DTILPrecision Biosciences Inc Q2 2021 · 10-Q
Revenue$68.81M$68.81M+6,282.7% vs Q2 2020 Net Income$21.66M$21.66MN/M vs Q2 2020 EPS Diluted$0.36$0.36N/M vs Q2 2020 Operating Income$21,632,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Precision Biosciences Inc · CIK 1357874 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$33,029,000N/M Margins · derivedOperating margin31.4%+3074.9 pt vs Q2 2020
Net margin31.5%+3065.0 pt vs Q2 2020
ended Jun 30, 2021 · filed Aug 12, 2021 · 43 d after period end